Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Older drugs may be good stopgap treatment for malaria in Africa

25.01.2006


A combination of older malaria drugs could treat malaria efficiently in some parts of Africa until a newer antimalarial drug called is widely available in those areas, a new review of recent studies suggests.



After 28 days of treatment, there were fewer cases of malaria among children taking a combination of the older sulfadoxine-pyrimethamine (sold under the brand name Fansidar) and amodiaquine than among patients taking a combination of Fansidar and artesunate, a drug based on the newer antimalarial called artemisinin.

However, the Fansidar-artesunate combination was more effective than the other drug combination at clearing malaria parasites from the blood at a particularly infectious stage of parasite development, according to Dr. Hasifa Bukirwa of the Uganda Malaria Surveillance Project and Julia Critchley of the Liverpool School of Tropical Medicine in England.


Bukirwa and Critchley say Fansidar-amodiaquine may be a useful stopgap treatment in areas without access to artemisinin drugs and areas where malaria resistance to Fansidar and amodiaquine is still low.

The review appears in the current issue of The Cochrane Library, a publication of The Cochrane Collaboration, an international organization that evaluates medical research. Systematic reviews draw evidence-based conclusions about medical practice after considering both the content and quality of existing medical trials on a topic.

Artemisinin antimalarials are fast-acting and effective drugs that have proved useful against multi-drug resistant strains of the falciparum type of malaria. The World Health Organization recommends combination therapy that includes artemisinin drugs as the standard treatment in countries where malaria is resistant to older individual drugs such as chloroquine and amodiaquine.

However, "artemisinin drugs are not yet widely available in Africa and may not be for some time because of low production, comparatively high cost, dosing complexity and the lack of clinical experience with artemisinin-based combinations," Bukirwa and Critchley say.

The Cochrane reviewers analyzed four studies including 775 malaria patients, children age six months to five years. The studies compared the Fansidar-amodiaquine treatment to Fansidar-artesunate therapy for mild to moderate cases of falciparum malaria.

In three of the studies, the Fansidar-amodiaquine treatment reduced by nearly 40 percent the risk of still having malaria after 28 days of treatment, compared to Fansidar-artesunate treatment.

But the Fansidar-artesunate combination was more than twice as likely as the other drug combination to reduce the number of infectious malaria parasites in the blood to clinically insignificant levels. Reducing the parasite load is important because it reduces the spread of the disease, the reviewers say.

Bukirwa and Critchley stress that the Fansidar-amodiaquine combination should be considered useful and safe only in areas where resistance to both drugs is low. They warn that resistance may have increased since the studies in the review, conducted between 2002 and 2005, were completed.

"It is possible that sulfadoxine-pyrimethamine may not be recommended at all for first-line treatment of any malaria in Africa in the future," Bukirwa said.

Although combination malaria therapies are also being tried in Southeast Asia, where malaria is a major public health problem, the Fansidar-amodiaquine combination is probably not a viable treatment option for that region, says Dr. David Bell, a malaria expert at the University of Liverpool in England.

The failure rates for both amodiaquine and Fansidar "on their own tend to be considerable higher there than when they are used in Africa as monotherapies," he explains. "As such, I don’t think the combination of amodiaquine and sulfadoxine-pyrimethamine would even be considered in that setting."

Malaria affects 300 to 500 million people worldwide every year and is the leading cause of illness and death in sub-Saharan Africa, according to a 2000 WHO report.

Hasifa Bukirwa | EurekAlert!
Further information:
http://www.cfah.org
http://www.cochrane.org

More articles from Health and Medicine:

nachricht Study suggests possible new target for treating and preventing Alzheimer's
02.12.2016 | Oregon Health & Science University

nachricht The first analysis of Ewing's sarcoma methyloma opens doors to new treatments
01.12.2016 | IDIBELL-Bellvitge Biomedical Research Institute

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Novel silicon etching technique crafts 3-D gradient refractive index micro-optics

A multi-institutional research collaboration has created a novel approach for fabricating three-dimensional micro-optics through the shape-defined formation of porous silicon (PSi), with broad impacts in integrated optoelectronics, imaging, and photovoltaics.

Working with colleagues at Stanford and The Dow Chemical Company, researchers at the University of Illinois at Urbana-Champaign fabricated 3-D birefringent...

Im Focus: Quantum Particles Form Droplets

In experiments with magnetic atoms conducted at extremely low temperatures, scientists have demonstrated a unique phase of matter: The atoms form a new type of quantum liquid or quantum droplet state. These so called quantum droplets may preserve their form in absence of external confinement because of quantum effects. The joint team of experimental physicists from Innsbruck and theoretical physicists from Hannover report on their findings in the journal Physical Review X.

“Our Quantum droplets are in the gas phase but they still drop like a rock,” explains experimental physicist Francesca Ferlaino when talking about the...

Im Focus: MADMAX: Max Planck Institute for Physics takes up axion research

The Max Planck Institute for Physics (MPP) is opening up a new research field. A workshop from November 21 - 22, 2016 will mark the start of activities for an innovative axion experiment. Axions are still only purely hypothetical particles. Their detection could solve two fundamental problems in particle physics: What dark matter consists of and why it has not yet been possible to directly observe a CP violation for the strong interaction.

The “MADMAX” project is the MPP’s commitment to axion research. Axions are so far only a theoretical prediction and are difficult to detect: on the one hand,...

Im Focus: Molecules change shape when wet

Broadband rotational spectroscopy unravels structural reshaping of isolated molecules in the gas phase to accommodate water

In two recent publications in the Journal of Chemical Physics and in the Journal of Physical Chemistry Letters, researchers around Melanie Schnell from the Max...

Im Focus: Fraunhofer ISE Develops Highly Compact, High Frequency DC/DC Converter for Aviation

The efficiency of power electronic systems is not solely dependent on electrical efficiency but also on weight, for example, in mobile systems. When the weight of relevant components and devices in airplanes, for instance, is reduced, fuel savings can be achieved and correspondingly greenhouse gas emissions decreased. New materials and components based on gallium nitride (GaN) can help to reduce weight and increase the efficiency. With these new materials, power electronic switches can be operated at higher switching frequency, resulting in higher power density and lower material costs.

Researchers at the Fraunhofer Institute for Solar Energy Systems ISE together with partners have investigated how these materials can be used to make power...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

ICTM Conference 2017: Production technology for turbomachine manufacturing of the future

16.11.2016 | Event News

Innovation Day Laser Technology – Laser Additive Manufacturing

01.11.2016 | Event News

#IC2S2: When Social Science meets Computer Science - GESIS will host the IC2S2 conference 2017

14.10.2016 | Event News

 
Latest News

UTSA study describes new minimally invasive device to treat cancer and other illnesses

02.12.2016 | Medical Engineering

Plasma-zapping process could yield trans fat-free soybean oil product

02.12.2016 | Agricultural and Forestry Science

What do Netflix, Google and planetary systems have in common?

02.12.2016 | Physics and Astronomy

VideoLinks
B2B-VideoLinks
More VideoLinks >>>